How many investments has Cardinal Partners made?

Cardinal Partners has 19 tracked investments, 10 of which have exited.

What stage does Cardinal Partners invest at?

Cardinal Partners invests at the Seed, Series A, Series B, Growth stages.

What sectors does Cardinal Partners focus on?

Cardinal Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is Cardinal Partners located?

Cardinal Partners is headquartered in Princeton, US.

Does Cardinal Partners lead rounds?

Yes, Cardinal Partners leads investment rounds.

Who does Cardinal Partners co-invest with?

Cardinal Partners most often shares deals with ARCH Venture Partners, Aspect Ventures, Bessemer Venture Partners, among 43 tracked co-investors.

Cardinal Partners

Venture capital

Princeton · Seed–Growth · 16 people tracked

Also known as CHP MANAGEMENT, INC.

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Cardinal Partners

Each arrow is one introduction. Sign up to fill in the first one.

22 people can intro you to John

Ask Alan Ezekowitz to introduce you to John Clarke

You →Alan · together at Vividion Therapeutics →John

12 people can intro you to Thomas

Ask Jamie Chen to introduce you to Thomas G. McKinley

You →Jamie · together at Life Image →Thomas

7 people can intro you to Paul

Ask Sam Okafor to introduce you to Paul Schimmel

You →Sam · together at aTYR PHARMA →Paul

John Park6 people can intro you
Arnold Milstein2 people can intro you

Your email: who you already know at Cardinal Partners, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Cardinal Partners team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

✨ Fox Verdict

Investment thesis

Cardinal Partners focuses on early and growth stage healthcare investing, backing disruptive healthcare technology-enabled services and life sciences companies. The firm often serves as the first institutional investor and occasionally plays a co-founding role at inception. Its thesis is driven by ongoing change across healthcare systems, insurance, and regulatory reform, favoring companies that deliver more care to more people at lower cost. Cardinal emphasizes deep healthcare investing experience, strong academic, clinical, industry, and investment networks, and sustained engagement with portfolio companies to build durable, valuable businesses through multiple economic cycles.

Invests inBiotech Digital Health Healthtech Medical Devices Princeton United States

Source: firm website, verified Sep 29, 2026.

Leave your own feedback

Stage

Seed–Growth

Princeton, New Jersey, US

Leads rounds

Leads

Instruments

Equity

Founded

1996

AUM

$400M

VC funds

Tracked investments

Unicorns

IPOs

Acquisitions

Team · 16 people

from the firm's website & public directories

John Clarke· Managing Partner· Alvin, Texas, United States

John Clarke is a Managing Partner at Cardinal Partners, which he co-founded in 1997, and brings over three decades of early-stage venture capital experience. He leads the firm's life sciences investment practice and has led or directed investments in multiple publicly traded pharmaceutical and healthcare companies. Prior to Cardinal, he spent 15 years at DSV Partners, where he managed the firm's healthcare and life sciences portfolio and served as interim CEO of several successful companies.

johnclarke@cardinalpartners.com

John Park· Partner & CFO· Philadelphia

John Park is Partner and CFO at Cardinal Partners, which he co-founded in 1997. He entered venture capital in 1992 as CFO of DSV Partners, where he became a General Partner in 1995. Before venture capital, he held financial and analytical roles at Day & Zimmermann, a Philadelphia-based services company, and in the oil and gas industry.

johnpark@cardinalpartners.com

Kent Marquardt· General Partner

kent@cardinalpartners.com

Thomas G. McKinley· General Partner

tom@cardinalpartners.com

Alan Ezekowitz

Arnold Milstein· Professor of Medicine at Stanford University· Stanford, California

Arnold Milstein is a Professor of Medicine at Stanford University, where he directs the Clinical Excellence Research Center, a collaboration between the Schools of Medicine and Engineering focused on designing health care delivery models that lower per capita spending and improve patient experience. Earlier, he founded a healthcare performance improvement firm later acquired by Mercer and co-founded the Leapfrog Group and the Consumer Purchaser Alliance. He served on the faculty of UCSF's Health Policy Institute, held a term as a MedPAC Commissioner, and holds a BA in Economics from Harvard, an MD from Tufts, and an MPH from UC Berkeley.

Diego Miralles· CEO, Laronde· La Jolla, CA

Diego Miralles, MD, PhD, is CEO of Laronde and previously served as President of Adaptive Therapeutics, where he built a therapeutics program on the Adaptive immunosequencing platform. He spent years at Johnson & Johnson beginning in 2005, working on drug development at Tibotec in Belgium, leading the Janssen Research and Early Development unit in La Jolla, and founding the JLABS incubator (2012) and Janssen Healthcare Innovation (2011). Earlier he held R&D roles at Trimeris and Triangle Pharmaceuticals and was an Assistant Professor at Duke University Medical Center; he holds an MD from the Universidad de Buenos Aires and is an Adjunct Professor of Pharmacology at UC San Diego.

Paul Schimmel· Professor of Biochemistry and Biophysics at MIT

Paul Schimmel is the Ernest and Jean Hahn Professor of Cell and Molecular Biology at The Scripps Research Institute, with campuses in Florida and California. He earned his PhD in biochemistry and biophysics from MIT in 1966 and previously held the John D. and Catherine T. MacArthur Professorship in MIT's Department of Biology. He has authored roughly 500 scientific papers and a three-volume textbook on biophysical chemistry, holds numerous patents, and has cofounded or served as founding director of several biotechnology companies, seven of which became NASDAQ-listed.

Antal R. Desai· Executive Officer

Clive Harris· Executive Officer

Faith Rosenfeld· Executive Officer

James Traweek· Director

John Bateman· Executive Officer

R. Kent McGaughy· Executive Officer

Richard Crawshaw· Executive Officer

Richard McGaughy· Director

What they invest in

from 12 of 19 portfolio companies

Healthtech ×9Biotech ×7Medical Devices ×7Digital Health ×6AI & Machine Learning ×2Enterprise Software ×2Data & Infrastructure ×1Deep Tech ×1

HQs:United States×12Denmark×1Ireland×1

Investments · 19 tracked

founders shown can be your intro path

By year:2019 · 1 2018 · 1 2016 · 1 2015 · 25 dated

aTYR PHARMAatyrpharma.com in 𝕏NASDAQ: ATYRMar 2015

aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.

BiotechHealthtechMedical DevicesSan Diego, US

Paul Schimmel(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)

Board Amir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)

Board seat Paul Schimmel John Clarke· per SEC Form D

Co-investorsEcoR1 Capital Sofinnova Ventures Domain Associates Domain Partners Polaris Partners Samsara BioCapital +1 more

Teladoc Healthteladoc.com in 𝕏NYSE: TDOCJul 2016

Teladoc Health operates a virtual care platform connecting patients with care providers for medical care, mental health, and chronic disease management services.

Digital HealthHealthtechMental HealthPurchase, US

Michael King(Executive Officer)inMark Hirschhorn(Executive Officer)in Jason Gorevic(Executive Officer, Director)inKevin Williamson(Executive Officer)inAdam Vandervoort(Executive Officer)in Daniel Trencher(Executive Officer)in

Board seatThomas G. McKinley· per SEC Form D

Co-investorsDria Ventures Harmonic Growth Partners HLM Investment Partners Kleiner Perkins New Capital Partners QuestMark Partners +2 more

Alkermesalkermes.com inNASDAQ: ALKS

Alkermes develops pharmaceutical medicines for psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders.

BiotechHealthtechMedical Devices

Richard F. Pops(Chairman of the Board, former CEO)Joshua Reed(Senior Vice President, Chief Financial Officer)in Blair C. Jackson(President & Chief Executive Officer)inDavid J. Gaffin(Executive Vice President, Chief Legal Officer and Chief Compliance Officer; Secretary)inCraig C. Hopkinson(Executive Vice President, Research and Development and Chief Medical Officer)C. Todd Nichols(Senior Vice President, Chief Commercial Officer)in

Partner John Clarke· led

Co-investorsBain Capital Life Sciences Vedanta Capital Hatteras Venture Partners

Alnylam Pharmaceuticalsalnylam.com in 𝕏NASDAQ: ALNY

Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.

BiotechDigital HealthMedical DevicesCambridge, US

John Maraganore(Founder)inPhillip Sharp(Founder)David Bartel(Founder)Thomas Tuschl(Founder)Paul Schimmel(Founder)Phillip Zamore(Founder)

Co-investorsARCH Venture Partners Atlas Venture Blackstone Life Sciences Invivo Capital Partners

Priviahealthpriviahealth.com in 𝕏NASDAQ: PRVA

Privia Health operates a network of physician practices organized for value-based care delivery, supporting independent practices and physicians across multiple specialties while maintaining clinical autonomy.

Data & InfrastructureDigital HealthEnterprise SoftwareHealthtechSaaSArlington, US

Jeff Butler(Founder)inParth Mehrotra(CEO)

Verastemverastem.com in 𝕏NASDAQ: VSTM

Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.

BiotechMedical DevicesNeedham, US

Robert WeinbergRICHARD ALDRICH(Director)AMY C. CAVERS(Executive Officer)in CATHY CAREW(Executive Officer)in JONATHAN PACHTER(Executive Officer)inROB GAGNON(Executive Officer)in

Partner John Clarke· led

Co-investorsBessemer Venture Partners Foresite Capital Lightstone Ventures Longwood Fund Oberland Capital OrbiMed

Athenahealth Incathenahealth.com in

Cloud-based healthcare platform for clinical workflows

Bob Segert in

Co-investorsAspect Ventures Bain Capital Double Impact Fund LP Bain Capital Tech Opportunities BCI Draper Associates Hellman & Friedman +8 more

Cureatrcureatr.com

New York, US

Joseph Mayer(Director)inJames Bradley(Director)Bharath Ganesan(Director)Richard Resnick(Executive Officer, Director)

Board John Clarke(Director)in Todd Pietri(Director)in

Co-investorsWindham Capital Partners Activate Venture Partners Activate Ventures

Ivenixivenix.com inSep 2015 · $42M

Ivenix makes an intelligent infusion pump system for hospital settings that delivers intravenous medications to patients while incorporating safeguards to reduce medication errors.

BiotechHealthtechMedical DevicesAmesbury, US

John Sokolowski(Executive Officer)inGeorge W. Gray(Executive Officer)Carolyn Malleck(Executive Officer)inJesse Ambrosina(Executive Officer)

Board Ketan Patel(Director)in John K. Clarke(Director)in

Co-investorsF-Prime Capital SCP Vitalife Partners ECO Fleet Holdings WuXi Healthcare Ventures

Life Imagelifeimage.com in 𝕏acquired by Intelerad

Life Image (now part of Intelerad, a GE HealthCare company) provides technology that connects physicians and moves medical imaging and data across the patient journey.

Digital HealthEnterprise SoftwareHealthtechMedical DevicesNewton, US

Hamid Tabatabaie(Executive Officer, Director, Promoter)in

BoardDavid Jahns(Director)Thomas McKinley(Director)William Cowen(Director)in

Co-investorsLRVHealth MassVentures Galen Partners

Prealizehealthprealizehealth.com in 𝕏

Prealize develops AI and machine learning solutions for healthcare providers and health plans to enable proactive, prediction-driven care rather than reactive treatment.

AI & Machine LearningDigital HealthHealthtechInsurTechStanford, US

Board Dr. Arnold MilsteinDr. Nigam Shah

Prexton Therapeuticsprextontherapeutics.com inacquired by Lundbeck

Prexton Therapeutics was a biopharmaceutical company developing novel therapies for Parkinson's disease, including its lead mGluR4 modulator candidate foliglurax.

BiotechHealthtechMedical DevicesCopenhagen, DK

Co-investorsM Ventures Seroba Life Sciences Sunstone Capital Ysios Capital Forbion

Sapphire Digitalsapphire-digital.com in 𝕏acquired by Zelis

The page discusses healthcare payment integrity topics such as fraud, waste and abuse detection and reducing improper payments, and references member communications tools for health plans.

Digital HealthFintechHealthtech

Vividion Therapeuticsvividion.com inApr 2019 · $82Macquired by Bayer

Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.

AI & Machine LearningBiotechDeep TechPrinceton, US

Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)Aleksandra Rizo(President and Chief Executive Officer)in

Board John Park(Executive Officer)John Clarke(Executive Officer, Director)in

Co-investorsARCH Venture Partners Avoro Capital Advisors Nextech Invest SoftBank Vision Fund Alexandria ALTITUDE LIFE SCIENCE VENTURES +4 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Cardinal Analytx3MLundbeckMomentapharmaQpidhealth

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 10

6 IPOs · 4 acquisitions

aTYR PHARMANASDAQ: ATYRTeladoc HealthNYSE: TDOCAlkermesNASDAQ: ALKSAlnylam PharmaceuticalsNASDAQ: ALNYPriviahealthNASDAQ: PRVAVerastemNASDAQ: VSTMLife Imageacq. by InteleradPrexton Therapeuticsacq. by LundbeckSapphire Digitalacq. by ZelisVividion Therapeuticsacq. by Bayer

Portfolio news

latest coverage across their companies

Alkermes to Report Second Quarter Financial Results on July 28, 2026 - BioSpace

Alkermes · biospace.com · Jul 15, 2026

Ivenix Infusion System Raises $ | SignalBase

Ivenix · trysignalbase.com · Mar 25, 2026

Fund performance · per public LP disclosures

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Cardinal NR Sidecar HoldingsLPs: New York City Fire Department Pension Fund, New York City Board of Education Retirement System	2018	—	17.2%	—	0.45x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

How many investments has Cardinal Partners made?: Cardinal Partners has 19 tracked investments, 10 of which have exited.
What stage does Cardinal Partners invest at?: Cardinal Partners invests at the Seed, Series A, Series B, Growth stages.
What sectors does Cardinal Partners focus on?: Cardinal Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Cardinal Partners located?: Cardinal Partners is headquartered in Princeton, US.
Does Cardinal Partners lead rounds?: Yes, Cardinal Partners leads investment rounds.
Who does Cardinal Partners co-invest with?: Cardinal Partners most often shares deals with ARCH Venture Partners, Aspect Ventures, Bessemer Venture Partners, among 43 tracked co-investors.

Images

Similar investors

Investinor

Investinor AS is a Norwegian investment company that partners with founders, entrepreneurs and other investors to help selected promising companies become world-leading.

RiverVest Venture Partners

RiverVest Venture Partners is a life sciences venture capital firm that invests in biotechnology and medical companies, working with entrepreneurs to advance therapeutic and medical innovations.

$500K – $3M

Pitango

Pitango is an Israel-based venture capital firm that has backed founders across technology sectors for decades, offering portfolio companies access to a broad network of customers, partners, and leaders.

$4M – $100M

Serra Ventures

Serra Ventures is an early-stage venture capital firm that also provides M&A advisory and consulting services to middle-market companies, with a strong focus on ag and food technology.

$5M

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

$540K – $27M